96
Participants
Start Date
March 21, 2019
Primary Completion Date
December 27, 2023
Study Completion Date
December 27, 2027
SBRT + Durvalumab
"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
SBRT
SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
Centre Georges François Leclerc, Dijon
CHRU de Brest, Brest
Institut Bergonie, Bordeaux
Institut de Cancérologie de Montpellier, Montpellier
ICO, Saint-Herblain
Chbs Lorient, Lorient
Centre Oscar Lambret, Lille
Hospices Civils de Lyon, Pierre-Bénite
Centre Léon Bérard, Lyon
Collaborators (1)
AstraZeneca
INDUSTRY
Institut Cancerologie de l'Ouest
OTHER